CD4 and metastatic melanoma: Interestingly, in our study, additional proof that further reinforces the role of CD26high as a biomarker in metastatic melanoma patients is the finding that lower baseline levels of CD4+CD26high T cells were correlated significantly with reduced OS and PFS in melanoma patients.